Phesgo
Aug 13, 2024
Roche’s HER2-Positive Breast Cancer Treatment Franchise
For most of the last century, breast cancer was categorized only by its location in the body; as a result, treatment results varied significantly. Patients with metastatic HER2+ breast cancer were traditionally treated with conventional chemotherapy regimens until trastuzumab became available. In September 1998, th...
Read More...
Jun 30, 2020
FDA’s No to Intercept’s NASH Drug; Roche’s Phesgo gets approval; Gilead’s Remdesivir pricing
Intercept Pharmaceuticals receives a clear rejection from the FDA for its NASH drug, Obeticholic acid (OCA) Intercept Pharmaceuticals announced the issuance of a Complete Response Letter (CRL) by the FDA regarding the New Drug Application (NDA) for Obeticholic acid (OCA) for the treatment of fibrosis due to ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
